PURPOSE: Hydronephrosis is a frequently observed but understudied complication in patients with cervical cancer. To better characterize hydronephrosis in cervical cancer patients, the current study sought (1) to describe hydronephrosis-associated morbidity and (2) to analyze the prognostic effect of hydronephrosis in patients with a broad range of cancer stages over time. METHODS: The Mayo Clinic Tumor Registry was interrogated for all invasive cervical cancer patients seen at the Mayo Clinic from 2008 through 2013 in Rochester, Minnesota; these patients' medical records were then reviewed in detail. RESULTS: Two hundred seventy-nine cervical cancer patients with a median age of 49 years and a range of cancer stages were included. Sixty-five patients (23 %) were diagnosed with hydronephrosis at some point during their disease course. In univariate analyses, hydronephrosis was associated with advanced cancer stage (p < 0.0001), squamous histology (p = 0.0079), and nonsurgical cancer treatment (p = 0.0039). In multivariate analyses, stage and tumor histology were associated with hydronephrosis. All but one patient underwent stent placement or urinary diversion; hydronephrosis-related morbidity included pain, urinary tract infections, nausea and vomiting, renal failure, and urinary tract bleeding. In landmark univariate survival analyses, hydronephrosis was associated with worse survival at all time points. In landmark multivariate analyses (adjusted for patient age, stage, cancer treatment, and tumor histology), hydronephrosis was associated with a trend toward worse survival over time (hazard ratios ranged from 1.47 to 4.69). CONCLUSION: Hydronephrosis in cervical cancer patients is associated with notable morbidity. It is also associated with trends toward worse survival-even if it occurs after the original cancer diagnosis.
PURPOSE:Hydronephrosis is a frequently observed but understudied complication in patients with cervical cancer. To better characterize hydronephrosis in cervical cancerpatients, the current study sought (1) to describe hydronephrosis-associated morbidity and (2) to analyze the prognostic effect of hydronephrosis in patients with a broad range of cancer stages over time. METHODS: The Mayo Clinic Tumor Registry was interrogated for all invasive cervical cancerpatients seen at the Mayo Clinic from 2008 through 2013 in Rochester, Minnesota; these patients' medical records were then reviewed in detail. RESULTS: Two hundred seventy-nine cervical cancerpatients with a median age of 49 years and a range of cancer stages were included. Sixty-five patients (23 %) were diagnosed with hydronephrosis at some point during their disease course. In univariate analyses, hydronephrosis was associated with advanced cancer stage (p < 0.0001), squamous histology (p = 0.0079), and nonsurgical cancer treatment (p = 0.0039). In multivariate analyses, stage and tumor histology were associated with hydronephrosis. All but one patient underwent stent placement or urinary diversion; hydronephrosis-related morbidity included pain, urinary tract infections, nausea and vomiting, renal failure, and urinary tract bleeding. In landmark univariate survival analyses, hydronephrosis was associated with worse survival at all time points. In landmark multivariate analyses (adjusted for patient age, stage, cancer treatment, and tumor histology), hydronephrosis was associated with a trend toward worse survival over time (hazard ratios ranged from 1.47 to 4.69). CONCLUSION:Hydronephrosis in cervical cancerpatients is associated with notable morbidity. It is also associated with trends toward worse survival-even if it occurs after the original cancer diagnosis.
Authors: Susan Atuhairwe; Robert B Busingye; Musa Sekikubo; Annettee Nakimuli; Twaha Mutyaba Journal: Int J Gynaecol Obstet Date: 2011-09-19 Impact factor: 3.561
Authors: M Morris; P J Eifel; J Lu; P W Grigsby; C Levenback; R E Stevens; M Rotman; D M Gershenson; D G Mutch Journal: N Engl J Med Date: 1999-04-15 Impact factor: 91.245
Authors: Peter G Rose; Shamshad Ali; Charles W Whitney; Rachelle Lanciano; Frederick B Stehman Journal: Gynecol Oncol Date: 2010-02-24 Impact factor: 5.482
Authors: Menke H Hazewinkel; Lieke Gietelink; Jacobus van der Velden; Matthé P M Burger; Jaap Stoker; Jan-Paul W R Roovers Journal: Gynecol Oncol Date: 2011-10-11 Impact factor: 5.482
Authors: Brooke Liang; Sara S Lange; L Stewart Massad; Rebecca Dick; Kathryn A Mills; Andrea R Hagemann; Carolyn K McCourt; Premal H Thaker; Katherine C Fuh; David G Mutch; Matthew A Powell; Lindsay M Kuroki Journal: Gynecol Oncol Rep Date: 2019-04-24
Authors: Leandro Nóbrega; Jeferson Rodrigo Zanon; Carlos E Eduardo Mattos da Cunha Andrade; Ronaldo Luis Schmidt; Marcelo Henrique Dos Santos; Ricardo Dos Reis Journal: Int J Gynecol Cancer Date: 2022-08-16 Impact factor: 4.661